IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.72
+0.06 (+0.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.66
Open10.64
Bid10.73 x 3000
Ask10.74 x 2900
Day's Range10.52 - 10.94
52 Week Range7.60 - 17.03
Volume865,115
Avg. Volume1,370,450
Market Cap1.668B
Beta (3Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire2 days ago

    Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced it will host its second quarter 2019 investor update conference call and webcast at 4:30 p.m. Eastern Time on Tuesday, July 30, 2019. Individuals interested in participating in the call should dial (866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international) using conference ID number 1896718. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

  • Business Wirelast month

    Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

    Ironwood Pharmaceuticals, Inc. (IRWD) and Allergan plc (AGN) today announced positive topline data from a Phase IIIb clinical trial evaluating LINZESS (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with IBS-C. The trial met its primary multi-component endpoint and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adult IBS-C patients compared to placebo. The trial also met both secondary endpoints.

  • Business Wirelast month

    Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced that the company plans to relocate its headquarters to a new office in downtown Boston from its current location in Cambridge, Massachusetts. Ironwood’s new headquarters will occupy approximately 39,000 square feet at 100 Summer Street. Ironwood anticipates the move to be completed in the fourth quarter of 2019, and expects to save more than $25 million in cash payments to its landlord over the following five years.

  • Business Wire2 months ago

    Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced the initiation of patient dosing in a Phase II clinical trial evaluating MD-7246 in patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D). Data from the Phase II trial are expected in the second half of 2020. Ironwood and Allergan are evaluating MD-7246, an investigational new product, as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with certain GI diseases.

  • Business Wire2 months ago

    Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019

    – IW-3718 Phase II data in patients with persistent GERD to be featured in oral presentation –

  • Business Wire2 months ago

    Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the 2019 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 14, 2019 at 8:00 a.m. Pacific Time at The Encore Hotel in Las Vegas. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required.

  • Business Wire3 months ago

    Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance

    – Ironwood launches as GI-focused healthcare company following separation of Cyclerion Therapeutics on April 1, 2019 –

  • Business Wire3 months ago

    Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced it will host its first quarter 2019 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 2, 2019. Individuals interested in participating in the call should dial (866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international) using conference ID number 8429338. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

  • Business Wire3 months ago

    Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced an adjustment to the conversion rate applicable to its existing 2.25% Convertible Senior Notes due 2022, effective April 15, 2019. The adjustment was effected pursuant to the indenture, dated as of June 15, 2015, and as supplemented April 5, 2019, between Ironwood and U.S. Bank National Association, as trustee, pursuant to which the Convertible Notes were originally issued. In connection with the separation of Ironwood and Cyclerion Therapeutics, Inc. (Cyclerion) into two independent, publicly traded companies, on April 1, 2019, Ironwood distributed to its shareholders one share of Cyclerion common stock for every 10 shares of Ironwood common stock held as of the close of business on March 19, 2019, the record date for the distribution.

  • Business Wire4 months ago

    Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion Therapeutics, Inc. (Cyclerion). Ironwood is executing on its strategy to drive growth as a GI-focused company, building upon its commercial success with LINZESS and advancing its late-stage, first-in-category development candidates including IW-3718 for the potential treatment of persistent gastroesophageal reflux disease (GERD) and MD-7246 for the potential treatment of abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D).

  • Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement
    Business Wire4 months ago

    Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc. (Cyclerion) has been declared effective by the U.S. Securities and Exchange Commission (SEC). The Form 10 reflects Ironwood’s plan for a tax-free spin-off of Cyclerion as a publicly-traded company, which is expected to be completed on April 1, 2019. The completion of the separation is set to occur through a distribution to Ironwood shareholders of one share of Cyclerion common stock for every 10 shares of Ironwood common stock held as of the close of business on March 19, 2019, the record date for the distribution.

  • Business Wire4 months ago

    Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 14, 2019 at 2:35 p.m. Eastern Time at The Loews Miami Beach Hotel in Miami. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

  • Business Wire5 months ago

    Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the 39th Annual Cowen Health Care Conference on Monday, March 11, 2019 at 4:10 p.m. Eastern Time at The Boston Marriott Copley Place in Boston. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

  • GlobeNewswire5 months ago

    Recent Analysis Shows Yamana Gold, Broadcom Inc., Atlas Air Worldwide, Hawaiian, H&E Equipment Services, and Ironwood Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering
    Business Wire5 months ago

    Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced that Cyclerion Therapeutics, Inc. (Cyclerion) has entered into an agreement for a private placement of up to $175 million. Final proceeds from this offering are expected to support Cyclerion’s sGC stimulator portfolio for at least two years, including four clinical data readouts expected in the second half of 2019. The financing transaction is anticipated to close in early April, immediately following the completion of Ironwood’s planned tax-free spin-off of Cyclerion to Ironwood shareholders.

  • Business Wire5 months ago

    Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

  • Business Wire5 months ago

    Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

    – Grew 2018 revenue 16% year-over-year to $347 million, driven primarily by U.S. LINZESS® collaboration revenue of $264 million and linaclotide API sales of $70 milli

  • Business Wire6 months ago

    Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call

    Ironwood Pharmaceuticals, Inc. today announced it will host its fourth quarter and full-year 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 13, 2019.

  • Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation
    Business Wire6 months ago

    Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced the filing by Cyclerion Therapeutics, Inc. (Cyclerion) of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). The Form 10 reflects Ironwood’s plan for a tax-free spin-off of Cyclerion as a publicly-traded company, which is on track to be completed in the first half of 2019. “Today’s filing is a critical step toward creating two differentiated, innovative and productive companies, each with promising foundational assets and the opportunity to build industry-leading businesses,” said Peter Hecht, chief executive officer of Ironwood and future chief executive officer of Cyclerion following completion of the planned separation.

  • GlobeNewswire6 months ago

    Investor Expectations to Drive Momentum within Hercules Capital, Alexandria Real Estate Equities, Ironwood Pharmaceuticals, 22nd Century Group, BorgWarner, and Forestar Group — Discovering Underlying Factors of Influence

    NEW YORK, Jan. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation
    Business Wire6 months ago

    Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced the composition of the Ironwood and Cyclerion Therapeutics, Inc. (“Cyclerion”) boards of directors, in connection with the previously announced planned business separation which is on track to be completed in the first half of 2019. Additionally, Ironwood announced that at its 2019 annual meeting of stockholders, the Ironwood board plans to recommend to its shareholders the elimination of its classified board and transition to a single class of directors to be elected annually.

  • Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials
    Business Wire6 months ago

    Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders. “The initiation of this Phase 1 study with IW-6463 marks an important milestone for our portfolio of next-generation sGC stimulators,” said Chris Wright, M.D., Ph.D., Ironwood’s current head of development and incoming chief medical officer and head of development of Cyclerion Therapeutics, Inc. (Cyclerion).

  • Business Wire6 months ago

    Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C

    Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotechnology company, today announced that the National Medical Products Administration (NMPA) approved the marketing application for LINZESS® (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) in China. Ironwood anticipates that it will launch the drug with its partner in China, AstraZeneca, in the second half of 2019.

  • Business Wire6 months ago

    Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced that Michael Shetzline, M.D., Ph.D., will join Ironwood as chief medical officer, senior vice president and head of drug development, effective January 28, 2019. Dr. Shetzline will lead global product development for Ironwood following its planned separation into two independent, publicly-traded companies.

  • Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
    Business Wire6 months ago

    Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced that the Ironwood board of directors has appointed chief executive officers (CEOs) of the two companies, effective at the time of Ironwood’s planned separation which is on track to be completed in the first half of 2019. Industry veteran Mark Mallon will become CEO and a director of Ironwood, a gastrointestinal (GI) healthcare company. Mr. Mallon is joining Ironwood effective immediately as executive senior advisor, working closely with Peter Hecht, founding CEO of Ironwood, through the separation.